Seno appoints CMO to help launch opto-acoustic cancer imaging tech
This article was originally published in Clinica
San Antonio, Texas-based Seno Medical Instruments has appointed William Keane as CMO, to spearhead the launch of its opto-acoustic imaging-based cancer detection technology, which is currently undergoing tests to support FDA approval. From this month, he will first oversee clinical studies underway at the Cancer Therapy & Research Center (part of the Texas Health Science Center), in San Antonio. In 2009, he will be responsible for launching further "pivotal trials". Dr Keane joins from Reliant Pharmaceuticals, where, as CMO, he helped the scientific/medical integration with GlaxoSmithKline.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.